AKR1A1 Antibody (B-9): sc-365078

AKR1A1 Antibody (B-9) is a mouse monoclonal IgG1 antibody that detects AKR1A1 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). AKR1A1, also known as aldo-keto reductase family 1 member A1, aldehyde reductase, dihydrodiol dehydrogenase 3, or alcohol dehydrogenase, is a crucial enzyme within the aldo-keto reductase family, which consists of soluble NADPH-dependent oxidoreductases that are vital for the metabolism of drugs, carcinogens, and reactive aldehydes. AKR1A1 primarily functions as a monomer, catalyzing the reduction of both xenobiotic and biogenic aldehydes and ketones to corresponding alcohols, with particular efficiency for medium-chain and aromatic aldehydes. Notably, AKR1A1 is involved in biosynthetic pathways of cholesterol and triglycerides, highlighting importance in lipid metabolism and cellular homeostasis. Additionally, AKR1A1 plays a significant role in the activation of polycyclic aromatic hydrocarbons (PAHs), which are known environmental pollutants with potential carcinogenic effects. Anti-AKR1A1 antibody (B-9) is an essential tool for researchers studying metabolic pathways and physiological roles of this enzyme, providing insights into contributions to health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

AKR1A1 Antibody (B-9) References:

1. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.  |  O'connor, T., et al. 1999. Biochem J. 343 Pt 2: 487-504. PMID: 10510318
2. Specifically immobilised aldo/keto reductase AKR1A1 shows a dramatic increase in activity relative to the randomly immobilised enzyme.  |  Holland-Nell, K. and Beck-Sickinger, AG. 2007. Chembiochem. 8: 1071-6. PMID: 17508367
3. Increased aldehyde reductase expression mediates acquired radioresistance of laryngeal cancer cells via modulating p53.  |  Kim, JS., et al. 2012. Cancer Biol Ther. 13: 638-46. PMID: 22555805
4. AKRs expression in peripheral blood lymphocytes from smokers: the role of body mass index.  |  Barrón-Vivanco, BS., et al. 2013. Hum Exp Toxicol. 32: 418-26. PMID: 22872607
5. Human aldo-keto reductases and the metabolic activation of polycyclic aromatic hydrocarbons.  |  Penning, TM. 2014. Chem Res Toxicol. 27: 1901-17. PMID: 25279998
6. Dimeric dihydrodiol dehydrogenase is an efficient primate 1,5-anhydro-D-fructose reductase.  |  Hara, A., et al. 2020. Biochem Biophys Res Commun. 526: 728-732. PMID: 32253031
7. A multienzyme S-nitrosylation cascade regulates cholesterol homeostasis.  |  Stomberski, CT., et al. 2022. Cell Rep. 41: 111538. PMID: 36288700
8. Mechanistic study of the Aldo-keto reductase family 1 member A1 in regulating mesenchymal stem cell fate decision toward adipogenesis and osteogenesis.  |  Chiang, CH., et al. 2024. Life Sci. 336: 122336. PMID: 38092142
9. Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study.  |  Yang, F., et al. 2023. Front Immunol. 14: 1203459. PMID: 38268915
10. A novel mitochondrial metabolism-related gene signature for predicting the prognosis of oesophageal squamous cell carcinoma.  |  Lin, W., et al. 2024. Aging (Albany NY). 16: 9649-9679. PMID: 38843392

The preferred AKR1A1 antibody is AKR1A1 Antibody (E-9): sc-271723.